J&J Weighs Topamax Controlled-Release After Dropping Obesity Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
J&J weighs Topamax controlled-release formulation after dropping obesity program. Phase II study in diabetes-related obesity shows no advantage for long-acting version, J&J says. Topiramate CR was designed to avoid dosing and tolerability issues seen in obesity trials with immediate-release
You may also be interested in...
Vivus Plans Evamist NDA In Q4 2006, But Obesity Combo Qnexa Is Top Priority
While Vivus is getting ready to submit its NDA for Evamist early in the fourth quarter of 2006, the company is calling its obesity drug Qnexa a potential blockbuster and earmarking it as its top priority.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product